BioAge Labs, Inc logo

BioAge Labs, Inc(BIOA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
2-STAR RATING
PASS
LAST CLOSE
$5.55
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BIOA

11/13/2026: BIOA (2-star) is currently NOT-A-BUY. Pass it for now.

BioAge Labs, Inc is a clinical-stage biotechnology company developing therapeutics that target the molecular drivers of aging to treat metabolic diseases such as obesity. Its primary growth opportunity rests on advancing its lead candidate, azelaprag, in combination studies designed to improve metabolic health and preserve muscle mass alongside standard weight-loss treatments. Key risks include an unproven commercial portfolio, an absence of current product revenues, and intense competition from well-capitalized pharmaceutical giants. The stock is best suited for growth-oriented investors with a high risk tolerance who can monitor upcoming clinical trial readouts and capital requirements. Overall, BioAge represents an innovative play on longevity science within the rapidly expanding metabolic disease market.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitBioAge offers high-growth potential tied to clinical readouts in the expanding obesity and metabolic therapeutics market.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp moves around clinical trial updates and biotech sector momentum shifts.
Value investorWeak fitThe company lacks earnings, commercial revenues, and traditional value metrics due to its clinical-stage status.
Dividend investorWeak fitBioAge does not pay dividends and retains all capital to fund drug development pipelines.
Low-risk investorWeak fitClinical-stage biotechnology stocks carry high regulatory, binary trial, and price volatility risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotech stocks fluctuate sharply based on trial results and market sentiment.
Valuation riskHighValuations are driven by pipeline potential rather than current revenues or earnings.
Competition riskHighWell-capitalized pharmaceutical giants dominate the obesity and metabolic therapeutic landscape.
Business qualityMediumThe company possesses innovative science and a robust discovery platform, though unproven commercially.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess depends heavily on successfully completing complex clinical trials and securing approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 255.03M USD
Price to earnings Ratio -
1Y Target Price 28.89
Price to earnings Ratio -
1Y Target Price 28.89
Volume (30-day avg) 822.9K shares
Beta 1.19
52 Weeks Range 4.81 - 25.95
Updated Date 11/15/2026
52 Weeks Range 4.81 - 25.95
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.56

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 242.26%
Avg. Invested days 35
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BIOA receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
BIOA has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-13.4%), weak cash generation (FCF margin -915.5%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
BIOA's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 1131.5% of revenue). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
BIOA's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-13.4%, negative) and free-cash-flow growth (-58.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 95.4% and approximately 85.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.77% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 6.20%
Cormorant Asset Management, LLC 5.20%
Sofinnova Ventures 4.99%
Jupiter Topco LLC 4.67%
Octagon Capital Advisors LP 3.80%

Unit Economics (Per $1K Revenue)

★★★★★
BIOA generates approximately $1,000 of gross profit, $-10,315 of operating income, and $-9,155 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
BIOA has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Pipeline DevelopmentFuture commercialization or licensing of drug candidates like azelaprag for metabolic diseases.The company currently has no commercial product sales and relies on capital raises and potential future milestone or product revenues.

Valuation

Trailing PE -
Forward PE -
Enterprise Value -26.34M
Price to Sales(TTM) 29.66
Enterprise Value -26.34M
Price to Sales(TTM) 29.66
Enterprise Value to Revenue 0.95
Enterprise Value to EBITDA -
Shares Outstanding 45.95M
Shares Floating 39.25M
Shares Outstanding 45.95M
Shares Floating 39.25M
Percent Insiders 2.77
Percent Institutions 95.42

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.